ClinicalTrials.gg
Not yet recruitingNCT06318884Updated Mar 22, 2024

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1 interventional study of SCTB35 injection in Non-Hodgkin Lymphoma, B-cell, sponsored by Sinocelltech Ltd.. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 195 studies in Lymphoma, Non-Hodgkin with a site in China — 82 open to participants now, 109 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
71st of 183
76 · median 58
Started
2024
with 17 others
Phase 1
79 of 195
33 open now
Primary completion
2026-10
later than 51 of 108 live
Registered
160th of 195
by date

Among the 195 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 71st largest by planned enrollment of the 183 interventional ones that give a count, is one of 18 that started in 2024, is one of 79 in phase 1, reaches primary completion later than 51 of the 108 other live ones, and was the 160th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

82 of the 195 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma.

Read the detailed description

This is the first-in-human study of SCTB35, containing the dose-escalation and dose-expansion parts. The escalation cohorts will be enrolled to explore the maximum tolerated dose and recommended phase II dose (RP2D). A Safety Monitoring Committee (SMC) will review the accumulated safety data and other available data, and make a recommendation to each dose level of SCTB35 in the escalation cohorts. The expansion cohorts will be initiated after the RP2D is confirmed, and to further compare the preliminary efficacy and safety of SCTB35 at two dose levels that appropriately recommended by SMC.

03

Conditions studied

  • Non-Hodgkin Lymphoma, B-cell

Keywords

  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the study only if all the following conditions are met:

  1. Age ≥ 18 years
  2. or cytologically confirmed CD20+ mature B-cell neoplasm

    For dose-escalation phase:

    1. De novo or transformed diffuse large B-cell lymphoma (DLBCL)
    2. High-grade B-cell lymphoma (HGBCL)
    3. Primary mediastinal large B-cell lymphoma (PMBCL)
    4. Follicular lymphoma (FL)
    5. Mantle cell lymphoma
    6. Small lymphocytic lymphoma (SLL)
    7. Marginal zone lymphoma (MZL) (nodal, extranodal or mucosa associated)

    For dose expansion phase:

    1. FL cohort: histologic confirmed FL grade 1, 2, or 3a at initial diagnosis without clinical or pathological evidence of transformation
    2. LBCL cohort: including histologic confirmed DLBCL, not otherwise specified (NOS), Epstein-Barr virus+ DLBCL, transformed DLBCL from indolent subtypes, HGBCL, NOS, double/triple-hit HGBCL, FL grade 3b, and PMBCL
  3. For dose-escalation phase:

    , progressive and/or refractory disease after adequate systemic therapy containing at least an anti-CD20 monoclonal antibody (e.g. rituximab)

    1. Patients must have exhausted or are ineligible for all standard therapeutic options
    2. Patients with indolent lymphoma (FL, MZL or SLL) must have a need for treatment initiation based on symptoms and/or disease burden

    For dose-expansion phase:

    Relapsed, progressive and/or refractory disease following ≥ 2 prior lines of adequate systemic therapy containing at least an anti-CD20 monoclonal antibody (e.g. rituximab)

  4. At least 1 measurable site of disease based on computed tomography (CT) or magnetic resonance imaging (MRI) (defined as a clearly nodal lesion with the long axis > 1.5 cm or extranodal lesion with the long axis > 1.0 cm). Lesions that have previously received radiotherapy can be considered measurable only after confirming the presence of progression or residual lesions. (for the dose-escalation phase: a evaluable site of disease is allowed).
  5. (ECOG) performance status 0, 1 or 2
  6. Adequate hepatic/hematologic/renal/cardiac functions indicated by laboratory values

    1. (ANC) ≥ 1.0 x 10\^9/L within 7 days before first dose of study drug (without growth factor support). There is an exception for patients with bone marrow involvement in which case ANC must be ≥ 0.75 x 10\^9/L
    2. > 75 x 10\^9/L within 7 days before first dose of study drug (without growth factor support or transfusion). There is an exception for patients with bone marrow involvement in which case platelets must be ≥ 50 x 10\^9/L
    3. > 90 g/L within 7 days before first dose of study drug (independent of growth factor support or transfusion).
    4. Serum creatinine ≤ 1.5 x (ULN) or ≥ 45 mL/min as estimated by Cockcroft-Gault equation
    5. Adequate liver function indicated by: i) (AST)/serum glutamic-oxaloacetic transaminase ≤ 3 x ULN; ii) Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase ≤ 3 x ULN; iii) Total level ≤ 1.5 x ULN (unless documented Gilbert's syndrome).
    6. ≥ 50%;
  7. Expected survival time is more than 3 months

Exclusion criteria

Exclusion Criteria:

A patient who conforms to any of the following criteria should be excluded from the study:

  1. Any prior therapy with an bispecific antibody of the same class
  2. Eligible for high dose chemotherapy with hematopoietic stem cell transplantation ()
  3. Known central nervous system (CNS) involvement by lymphoma
  4. Known past or current other than inclusion diagnosis, with the following exceptions:

    1. Cervical carcinoma of Stage Ib or less
    2. Non-invasive basal cell or squamous cell skin carcinoma
    3. Non-invasive, superficial bladder cancer
    4. Prostate cancer with a current prostate-specific antigen (PSA) level \<0.1 ng/mL
    5. Any curable cancer with a complete response (CR) of >2 years duration
  5. Known cardiac disease, including:

    1. Onset of unstable angina pectoris or acute myocardial infarction within 6 months prior to signing Form (ICF)
    2. Congestive heart failure prior to signing ICF (meets the criteria of Classification III or IV)
    3. Clinically significant arrhythmia prior to signing ICF
  6. History of interstitial lung disease or uncontrolled lung diseases, or evidence of dyspnea at rest or pulse oximetry \< 93% while breathing room air.
  7. Confirmed history or current disease or other diseases resulting in permanent or requiring permanent immunosuppressive therapy (including >20mg/day prednisolone [or equivalent], but low-dose prednisolone is allowed). The well controlled autoimmune disease can be enrolled at investigator's discretion, including:

    1. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone
    2. Patients with a history of type 1 diabetes mellitus who were well controlled (defined as a screening \< 8% and no urinary ketoacidosis)
    3. Patients with skin disease who were not treated with systemic
  8. History of seizure disorder or confirmed progressive multifocal leukoencephalopathy (PML)
  9. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  10. Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks prior to signing ICF
  11. Positive for (HIV) antibody. Positive for antibody (except for only the positive HBsAb) with detectable hepatitis B virus (HBV) DNA. Positive for antibody with detectable hepatitis C virus (HCV) RNA
  12. Chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to first SCTB35 administration (only applicable for dose-expansion phase)
  13. Autologous HSCT within 100 days prior to first SCTB35 administration, or any prior allogeneic HSCT or solid organ transplantation
  14. Received major surgery within 4 weeks prior to first SCTB35 administration, or planned to receive major surgery during the study
  15. Received any chemotherapeutic agent, other anti-cancer agent, or drug (monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first SCTB35 administration
  16. Exposed to live or within 4 weeks prior to first SCTB35 administration, or planned to receive these vaccines during the study
  17. Pregnancy or breast feeding. During the study and for 6 months after last administration of SCTB35, a woman of or a man who is sexually active with a woman of childbearing potential disagrees to practice a highly effective method of .
  18. Patient has any condition for that, in the opinion of the investigator, participation could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    SCTB35

    SCTB35 injection is subcutaneously given every week for the first 4 cycles, and thereafter every 3 weeks. Cycles will be repeated every 3 weeks until disease progression, study discontinuation, or death, whichever occurs first.

    Drug: SCTB35 injection

Interventions

  • SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.

    Also known as: none other names

06

What researchers measure

Primary outcomes

  1. Dose-escalation part: dose limited toxicity (DLT)

    To determine the maximum tolerated dose (MTD) and/or RP2D to be studied in the dose-expansion part

    Time frame: During the first cycle (21 days)

  2. Dose-escalation part: incidence rate of adverse event (AE)

    To evaluate the incidence rates of treatment emergent adverse event (TEAE), treatment-related TEAE (TRAE), serious adverse event (SAE), adverse event with special interest (AESI)

    Time frame: From first dose until 28 days after last dose of study drug or until study completion or participant withdrawal (up to 3 years)

  3. Dose-expansion part: objective response rate (ORR)

    ORR is defined as the percentage of patients achieving complete response (CR) or partial response (PR) as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

Secondary outcomes

  1. Dose-escalation part: ORR

    ORR is defined as the percentage of patients achieving CR or PR as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  2. Dose-escalation part: CR rate (CRR)

    CR rate is defined as the percentage of patients with CR as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  3. Dose-escalation part: best of overall response (BOR)

    BOR is defined as the percentage of patients achieving best response from the first dose to first documented disease progression (PD) or new anticancer therapy, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  4. Dose-escalation part: duration of response (DOR)

    DOR is defined as the time from first documented objective response to PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  5. Dose-escalation part: progression-free survival (PFS)

    PFS is defined as the time from first dose to first documented PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  6. Dose-escalation part: time to response (TTR)

    TTR is defined as the time from first dose to first documented objective response observed for patients who achieved a CR or PR, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  7. Dose-escalation part: overall survival (OS)

    OS is defined as the time from first dose to death due to any cause

    Time frame: From first dose until up to 5 years

  8. Dose-escalation part: blood concentrations of SCTB35

    The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)

    Time frame: From first dose until up to 2 years

  9. Dose-escalation part: anti-drug antibodies of SCTB35

    Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35

    Time frame: From first dose until up to 2 years

  10. Dose-expansion part: CRR

    CR rate is defined as the percentage of patients with CR as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  11. Dose-expansion part: BOR

    BOR is defined as the percentage of patients achieving best response from the first dose to first documented PD or new anticancer therapy, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  12. Dose-expansion part: DOR

    DOR is defined as the time from first documented objective response to PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  13. Dose-expansion part: PFS

    PFS is defined as the time from first dose to first documented PD or death due to any cause, whichever occurs first, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  14. Dose-expansion part: TTR

    TTR is defined as the time from first dose to first documented objective response observed for patients who achieved a CR or PR, as determined by the investigator according to the Lugano Criteria 2014

    Time frame: From first dose until up to 2 years

  15. Dose-expansion part: OS

    OS is defined as the time from first dose to death due to any cause

    Time frame: From first dose until up to 5 years

  16. Dose-expansion part: AE

    To evaluate the incidence rates of TEAE, TRAE, SAE, AESI

    Time frame: From first dose until up to 2 years

  17. Dose-expansion part: blood concentrations of SCTB35

    The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)

    Time frame: From first dose until up to 2 years

  18. Dose-expansion part: anti-drug antibodies of SCTB35

    Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35

    Time frame: From first dose until up to 2 years

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Oct 2026, 30 months later.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 30 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartEst.
Apr 2024
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06318884
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Apr 2024 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 22, 2024

Study contacts

Junfan Ma, Ph.D
Contact
junfan_ma@sinocelltech.com
86-010-58628288
Yuqin Song, M.D.
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SCTB35

Start the discussion